Reflecting on progress and partnerships at Immutep

Reflecting on progress and partnerships at Immutep

[videojs_hls url=’//du7x25at22z7c.cloudfront.net/491844/index_HLSv3.m3u8′ poster=’http://www.finnewsnetwork.com.au/newssystem/2024/Int_IMM_360_241126.jpg’]

 

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network


Source: Finance News Network

Share this post